Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 19 de 19
Filter
1.
Aust Dent J ; 53(3): 196-200; quiz 297, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18782362

ABSTRACT

New Australian guidelines for the prevention of infective endocarditis were published in July 2008. The guidelines were revised by a multidisciplinary group to reflect recent changes in international recommendations regarding antibiotic prophylaxis for infective endocarditis. The reasons for the changes are explored in this review and the implications for dental practice are discussed.


Subject(s)
Antibiotic Prophylaxis/statistics & numerical data , Endocarditis, Bacterial/prevention & control , American Heart Association , Australia , Dental Care for Chronically Ill , Humans , Practice Guidelines as Topic , United States
2.
J Antimicrob Chemother ; 62(3): 608-16, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18550680

ABSTRACT

OBJECTIVES: Antibiotic stewardship is important, but the ideal strategy for providing stewardship in a hospital setting is unknown. A practical, sustainable and transferable strategy is needed. This study evaluates the impact of a novel computerized antimicrobial approval system on antibiotic-prescribing behaviour in a hospital. Effects on drug consumption, antibiotic resistance patterns of local bacteria and patient outcomes were monitored. METHODS: The study was conducted at a tertiary referral teaching hospital in Melbourne, Australia. The system was deployed in January 2005 and guided the use of 28 restricted antimicrobials. Data were collected over 7 years: 5 years before and 2 years after deployment. Uptake of the system was evaluated using an in-built audit trail. Drug utilization was prospectively monitored using pharmacy data (as defined daily doses per 1000 bed-days) and analysed via time-series analysis with segmental linear regression. Antibiograms of local bacteria were prospectively evaluated. In-hospital mortality and length of stay for patients with Gram-negative bacteraemia were also reported. RESULTS: Between 250 and 300 approvals were registered per month during 2006. The gradients in the use of third- and fourth-generation cephalosporins (+0.52, -0.05, -0.39; P < 0.01), glycopeptides (+0.27, -0.53; P = 0.09), carbapenems (+0.12, -0.24; P = 0.21), aminoglycosides (+0.15, -0.27; P < 0.01) and quinolones (+0.76, +0.11; P = 0.08) all fell after deployment, while extended-spectrum penicillin use increased. Trends in increased susceptibility of Staphylococcus aureus to methicillin and improved susceptibility of Pseudomonas spp. to many antibiotics were observed. No increase in adverse outcomes for patients with Gram-negative bacteraemia was observed. CONCLUSIONS: The system was successfully adopted and significant changes in antimicrobial usage were demonstrated.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Bacterial Infections/drug therapy , Drug Utilization Review/methods , Drug Utilization/statistics & numerical data , Medical Order Entry Systems , Australia , Bacteria/drug effects , Bacteria/isolation & purification , Bacterial Infections/microbiology , Bacterial Infections/mortality , Drug Resistance, Bacterial , Hospitals, Teaching , Humans , Length of Stay/statistics & numerical data , Microbial Sensitivity Tests , Statistics as Topic , Treatment Outcome
3.
Intern Med J ; 38(3): 174-7, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18290813

ABSTRACT

BACKGROUND: Community acquired pneumonia is one of the most common infections for which antibiotics are prescribed in Australia. METHODS: We audited empiric antibiotic prescribing for 392 adults with community-acquired pneumonia. RESULTS: Only 61.9% of patients received empiric antibiotic coverage for both typical and atypical pathogens. Of those who required intensive care unit management, 34.6% did not receive antibiotic cover for atypical pneumonia pathogens within the first 24 h. Approximately 21.9% of patients reporting antibiotic allergies were given antibiotics to which they had a documented allergy. CONCLUSION: Efforts to improve prescribing practices could be focused towards identifying patients with severe illness early and improving recognition of documented allergies.


Subject(s)
Anti-Infective Agents/therapeutic use , Community-Acquired Infections/drug therapy , Pneumonia/drug therapy , Practice Patterns, Physicians' , Adolescent , Adult , Aged , Aged, 80 and over , Community-Acquired Infections/microbiology , Emergency Service, Hospital , Female , Humans , Male , Medical Audit , Middle Aged , Pneumonia/microbiology
5.
Thorax ; 61(5): 419-24, 2006 May.
Article in English | MEDLINE | ID: mdl-16449258

ABSTRACT

BACKGROUND: Several severity scores have been proposed to predict patient outcome and to guide initial management of patients with community acquired pneumonia (CAP). Most have been derived as predictors of mortality. A study was undertaken to compare the predictive value of these tools using different clinically meaningful outcomes as constructs for "severe pneumonia". METHODS: A prospective cohort study was performed of all patients presenting to the emergency department with an admission diagnosis of CAP from March 2003 to March 2004. Clinical and laboratory features at presentation were used to calculate severity scores using the pneumonia severity index (PSI), the revised American Thoracic Society score (rATS), and the British Thoracic Society (BTS) severity scores CURB, modified BTS severity score, and CURB-65. The sensitivity, specificity, positive and negative predictive values were compared for four different outcomes (death, need for ICU admission, and combined outcomes of death and/or need for ventilatory or inotropic support). RESULTS: 392 patients were included in the analysis; 37 (9.4%) died and 26 (6.6%) required ventilatory and/or inotropic support. The modified BTS severity score performed best for all four outcomes. The PSI (classes IV+V) and CURB had a very similar performance as predictive tools for each outcome. The rATS identified the need for ICU admission well but not mortality. The CURB-65 score predicted mortality well but performed less well when requirement for ICU was included in the outcome of interest. When the combined outcome was evaluated (excluding patients aged >90 years and those from nursing homes), the best predictors were the modified BTS severity score (sensitivity 94.3%) and the PSI and CURB score (sensitivity 83.3% for both). CONCLUSIONS: Different severity scores have different strengths and weaknesses as prediction tools. Validation should be done in the most relevant clinical setting, using more appropriate constructs of "severe pneumonia" to ensure that these potentially useful tools truly deliver what clinicians expect of them.


Subject(s)
Pneumonia, Bacterial/diagnosis , Severity of Illness Index , Adolescent , Adult , Aged , Aged, 80 and over , Cohort Studies , Community-Acquired Infections/diagnosis , Community-Acquired Infections/mortality , Female , Humans , Male , Middle Aged , Pneumonia, Bacterial/mortality , Prognosis , Prospective Studies , Sensitivity and Specificity
6.
Emerg Med J ; 21(2): 170-4, 2004 Mar.
Article in English | MEDLINE | ID: mdl-14988341

ABSTRACT

OBJECTIVES: To determine outcomes and markers of serious illness for febrile patients presenting to an adult emergency department. METHODS: A prospective cohort study of patients presenting to the emergency department with a temperature >or=38 degrees C. Medical staff obtained demographic data and risk factor profiles while assessing each febrile patient. All were followed up to determine death, admission to intensive care, length of stay in hospital, or subsequent admission to hospital within 30 days. Univariate and multivariate analysis determined which factors were markers of serious illness. RESULTS: For febrile adults admitted to hospital 3.0% died, 6.1% were admitted to intensive care, median length of stay in hospital was 7.2 days. Independent risk factors were-death: age (OR = 1.04), respiratory rate (OR = 1.06), white cell count (OR = 1.02), cardiac disease (OR = 3.3), and jaundice (OR = 21.4). Admission to intensive care: respiratory rate (OR = 1.1), pulse rate (OR = 1.03), and jaundice (OR = 5.1). Increased length of hospital stay: age (p<0.01), jaundice (p<0.01), respiratory rate (p = 0.01), focal neurological signs (p = 0.01), and changed mental state (p = 0.04). For febrile adults sent home 7.9% required admission to hospital within 30 days. Risk factors were respiratory rate (OR = 1.2), being female (OR = 5.36), malignancy (OR = 15.3), and cardiac disease (OR = 19.7). Initially having no focus of infection was protective (OR = 0.13). No febrile patient sent home from the emergency department died or required admission to intensive care. CONCLUSIONS: Few febrile adults presenting to the emergency department suffer an adverse outcome suggesting effective risk stratification is occurring. The identification of factors associated with adverse events may further improve this process.


Subject(s)
Fever/mortality , Adult , Critical Care , Emergencies , Emergency Service, Hospital , Female , Fever/complications , Fever/physiopathology , Humans , Length of Stay , Male , Middle Aged , Odds Ratio , Prognosis , Prospective Studies , Respiration , Risk Factors
9.
Clin Infect Dis ; 27(2): 391-3, 1998 Aug.
Article in English | MEDLINE | ID: mdl-9709894

ABSTRACT

Neurocysticercosis is the most common parasitic infection of the central nervous system in humans. The adult pork tape worm, Taenia solium, resides in the lumen of the intestine, and the only structural element of an adult worm usually found within a tissue cyst in the brain or in muscle is a single invaginated scolex. We report a highly unusual, and perhaps unique, occurrence of neurocysticercosis in which an aberrant worm-like larval form, 12.5 cm in length, was found within a cyst in brain parenchyma.


Subject(s)
Brain Diseases/parasitology , Cysts/parasitology , Neurocysticercosis/diagnosis , Taenia/isolation & purification , Animals , Humans , Larva , Male , Middle Aged
11.
Epidemiol Infect ; 119(3): 313-8, 1997 Dec.
Article in English | MEDLINE | ID: mdl-9440434

ABSTRACT

Mycobacterium ulcerans, the organism which causes Buruli or Bairnsdale ulcer, has never been isolated in culture from an environmental sample. Most foci of infection are in tropical regions. The authors describe the first 29 cases of M. ulcerans infection from a new focus on an island in temperate southern Australia, 1992-5. Cases were mostly elderly, had predominantly distal limb lesions and were clustered in a small region in the eastern half of the main town on the island. The authors suspected that an irrigation system which lay in the midst of the cluster was a source of infection. Limitation of irrigation was associated with a dramatic reduction in the number of new cases. These findings support the hypothesis that M. ulcerans has an aquatic reservoir and that persons may be infected directly or indirectly by mycobacteria disseminated locally by spray irrigation.


Subject(s)
Disease Outbreaks , Mycobacterium Infections, Nontuberculous/epidemiology , Mycobacterium ulcerans/isolation & purification , Water Microbiology , Adolescent , Adult , Aged , Aged, 80 and over , Child , Child, Preschool , Female , Golf , Humans , Male , Middle Aged , Mycobacterium Infections, Nontuberculous/microbiology , Recreation , Seasons , Victoria/epidemiology , Water Supply
12.
Scand J Infect Dis ; 28(2): 199-203, 1996.
Article in English | MEDLINE | ID: mdl-8792493

ABSTRACT

We report 3 cases of Helicobacter cinaedi bacteraemia in different hosts representing a spectrum of clinical illness associated with this infection. The first was an AIDS patient with relapsing H. cinaedi bacteraemia despite antibiotic treatment. The second was an HIV seronegative homosexual man with end-stage renal failure, receiving haemodialysis and a previous history of chronic lymphoedema of his legs. He developed H. cinaedi bacteraemia with cellulitis of his left leg. Patient 3, an HIV seronegative homosexual man, had transient H. cinaedi bacteraemia 2 days after the completion of a course of chemotherapy for bilateral testicular carcinoma. The clinical spectrum of disease associated with H. cinaedi is broad, with few specific clinical features. Successful recovery of this fastidious organism from blood aids in the diagnosis of this unusual infection.


Subject(s)
AIDS-Related Opportunistic Infections/diagnosis , Bacteremia/complications , Helicobacter Infections/complications , Helicobacter/isolation & purification , Kidney Failure, Chronic/complications , Testicular Neoplasms/complications , AIDS-Related Opportunistic Infections/drug therapy , AIDS-Related Opportunistic Infections/physiopathology , Adult , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Bacteremia/diagnosis , Bacteremia/drug therapy , Fatal Outcome , HIV Seronegativity , Helicobacter/drug effects , Helicobacter Infections/diagnosis , Helicobacter Infections/drug therapy , Homosexuality, Male , Humans , Kidney Failure, Chronic/therapy , Male , Microbial Sensitivity Tests , Testicular Neoplasms/diagnosis , Testicular Neoplasms/therapy
14.
Vaccine ; 11(12): 1229-32, 1993 Sep.
Article in English | MEDLINE | ID: mdl-8256504

ABSTRACT

Patients undergoing chronic haemodialysis are at increased risk for infection with hepatitis B virus (HBV), but response to currently available vaccines is suboptimal. We undertook a 4-year prospective study of the efficacy of hepatitis B vaccine in patients with renal insufficiency, who were not yet dialysis-dependent. A booster dose of Recombivax HB was given at 3 or 4 years to those whose antibody levels fell below a predetermined point. Progression to dialysis was associated with poorer initial response to vaccination compared with those remaining dialysis-independent, but response to booster immunization was favourable in both groups. It is concluded that immunization of predialysis patients and subsequent booster vaccine results in a more favourable antibody response than has been seen historically in haemodialysis patients. Local endemicity and cost of vaccine should be considered when determining the best strategy for HBV immunization of patients with chronic renal failure.


Subject(s)
Hepatitis B Vaccines/therapeutic use , Renal Dialysis , Vaccination , Vaccines, Conjugate/therapeutic use , Cohort Studies , Female , Hepatitis B/prevention & control , Hepatitis B Antibodies/analysis , Hepatitis B Antibodies/biosynthesis , Humans , Male , Middle Aged , Prospective Studies , Renal Insufficiency/complications , Renal Insufficiency/immunology , Risk Factors
17.
Infect Control Hosp Epidemiol ; 11(10): 525-30, 1990 Oct.
Article in English | MEDLINE | ID: mdl-2146315

ABSTRACT

A cross-sectional serological survey was undertaken in 82 randomly selected high-risk healthcare workers previously vaccinated with the hepatitis B vaccine. The study design allowed for the identification and testing for hepatitis B surface antibody in equal numbers of employees in six-month intervals up to five years after vaccination. The results showed a consistent decline in antibody level with time, and an increasing proportion of participants with antibody levels below the commonly accepted protective level of greater than or equal to 10 S/N (sample counts/negative control counts) radioimmunoassay units. The percent of vaccinees whose S/N ratio was greater than 10 fell from 10% at one year, to 25% at two years, to over 50% at four years. Based on these figures, as well as the financial costs of hepatitis B in employees and the predictability of booster immunization, it was possible to assess the cost benefit of a hospital policy for reimmunization. At our institution, a strategy of revaccination at fixed intervals could save up to $200,000 over a ten-year period if revaccination was not offered and vaccine efficacy declined. The information obtained should help determine the need for revaccination and the advantages and disadvantages of alternative revaccination strategies.


Subject(s)
Hepatitis B Surface Antigens/analysis , Hepatitis B/immunology , Personnel, Hospital , Viral Hepatitis Vaccines/immunology , Adult , Cross-Sectional Studies , Female , Hepatitis B/prevention & control , Hepatitis B Vaccines , Hospital Bed Capacity, 500 and over , Humans , Immunization, Secondary/economics , Male , North Carolina , Somatotypes , Vaccination/statistics & numerical data
18.
N C Med J ; 50(3): 161-3, 1989 Mar.
Article in English | MEDLINE | ID: mdl-2710226

ABSTRACT

Hepatitis B is an important sexually transmitted disease. The availability of a safe and effective vaccine has unfortunately had little impact on controlling this disease nationwide or in North Carolina, chiefly because target groups have proven difficult to reach. Both HAV and NANB can be transmitted sexually, but are much less important than HBV.


Subject(s)
Hepatitis B virus , Hepatitis, Viral, Human/epidemiology , Sexually Transmitted Diseases/epidemiology , Hepatitis, Viral, Human/diagnosis , Hepatitis, Viral, Human/prevention & control , Humans , North Carolina , Sexually Transmitted Diseases/diagnosis , Sexually Transmitted Diseases/prevention & control
19.
Rev Infect Dis ; 10(5): 915-21, 1988.
Article in English | MEDLINE | ID: mdl-3055189

ABSTRACT

The published experience with trimethoprim-sulfamethoxazole (TMP-SMZ) for treatment of infective endocarditis was reviewed. Among 62 cases, a high proportion had unusual causative organisms: 60% of cases were due to Coxiella burnetii or Pseudomonas species. Only 17% of patients had previously normal cardiac valves. Patients often had complicated courses in which TMP-SMZ was tried only after other treatment regimens had failed, yet a successful outcome was achieved in 61% of cases. Thirty-five patients were treated with antibiotics alone, while the other 27 patients required combined medical and surgical management. TMP-SMZ has a limited role in the management of infective endocarditis; specific guidelines for its use, including proper laboratory control, have been delineated.


Subject(s)
Anti-Infective Agents/therapeutic use , Endocarditis, Bacterial/drug therapy , Sulfamethoxazole/therapeutic use , Trimethoprim/therapeutic use , Drug Combinations/therapeutic use , Humans , Trimethoprim, Sulfamethoxazole Drug Combination
SELECTION OF CITATIONS
SEARCH DETAIL
...